Apicore US Funding: How Much Did They Raise & Key Investors

How Much Did Apicore US Raise?
Funding & Key Investors

Apicore US has solidified its position within the pharmaceutical manufacturing sector, securing a total capital infusion of $16.7M. This trajectory of financial backing, which includes a recent strategic investment of $720K, underscores the company's critical role in the global supply chain for complex chemical synthesis. By leveraging these resources, the firm continues to expand its footprint in the development of high-value Active Pharmaceutical Ingredients, ensuring robust operational capacity across its international facilities.

The company's financial history reflects a steady progression, beginning with significant capital injections in 2014 and culminating in the most recent private equity financing round in 2016. This sustained investment interest highlights the market's confidence in Apicore's specialized manufacturing model and its ability to navigate the rigorous regulatory landscape of the pharmaceutical industry.

What is Apicore US?

Apicore US

Manufacturing

Pharmaceuticals

Chemicals & Related Products

Apicore US operates as a premier developer and manufacturer of specialty Active Pharmaceutical Ingredients (APIs), serving both generic and branded pharmaceutical entities. Headquartered in New Jersey, the company maintains a sophisticated infrastructure, including two FDA-approved facilities that facilitate production ranging from small-scale research quantities to large-scale commercial volumes. With a portfolio encompassing over 100 distinct APIs and a significant number of Abbreviated New Drug Applications (ANDAs), Apicore distinguishes itself through its expertise in synthesizing difficult-to-produce compounds. Their operational strategy integrates state-of-the-art analytical research with high-capacity manufacturing, positioning them as a vital partner for companies requiring niche pharmaceutical components that meet stringent international quality standards.

How much funding has Apicore US raised?

Apicore US has raised a total of $16.7M across 3 funding rounds:

2014

Unspecified

$9.2M

Unspecified

$6.8M

2016

Private Equity

$720K

Unspecified (2014): $9.2M with participation from Undisclosed

Unspecified (2014): $6.8M led by Undisclosed

Private Equity (2016): $720K, investors not publicly disclosed

Key Investors in Apicore US

Undisclosed Investors

What's next for Apicore US?

Looking ahead, Apicore US is well-positioned to leverage its recent capital influx to further optimize its manufacturing throughput and expand its portfolio of FDA-approved products. The strategic focus will likely remain on scaling production capabilities at its Vadodara and Somerset facilities to meet the increasing global demand for complex APIs. By continuing to invest in research and development, the company aims to strengthen its competitive advantage in the niche pharmaceutical market, potentially accelerating the commercialization of its pipeline. As the firm matures, its ability to maintain high-quality standards while scaling operations will be the primary driver of its long-term enterprise value and market influence.

See full Apicore US company page

See More Financial Insights